Hims & Hers Health (HIMS) has two strategic options to choose from post earnings, including aggressive expansion of personalized semaglutide weight loss business or reinvest in its existing core business, BofA Securities said in a note on Tuesday.
The firm said that expanding GLP-1 offerings could help the company beat guidance, but it also revives litigation risk related to compounding practices. Meanwhile, focusing on the core could stabilize long-term growth but likely result in lower near-term revenue.
Upcoming product launches and updates around compounded GLP-1s are key drivers for the remainder of 2025 and into 2026, according to the note.
Future growth will likely hinge on the success of new treatments for menopause, liraglutide, testosterone therapy, as well as efficient customer acquisition and capital deployment strategies, BofA added.
The firm reiterated its underperform rating on Hims & Hers' stock and raised the price target to $28 from $26.
Price: 46.43, Change: +4.55, Percent Change: +10.86
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。